Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT ID: NCT05609968
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
614 participants
INTERVENTIONAL
2023-02-06
2028-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Sacituzumab Govitecan
Participants receive sacituzumab govitecan 10mg/kg intravenous (IV) infusion once weekly on Day 1 and Day 8 of a continuous 21-day cycle until progressive disease (PD) requiring discontinuation, unacceptable toxicity, withdrawal of consent, or death. Participants receive pembrolizumab 200mg IV infusion on Day 1 every 3 weeks (Q3W) for up to 35 cycles (each cycle length = 21 days).
Sacituzumab Govitecan
IV infusion
Pembrolizumab
IV infusion
Pembrolizumab
Participants receive pembrolizumab 200mg IV infusion on Day 1 Q3W for up to 35 cycles (each cycle length = 21 days).
Pembrolizumab
IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab Govitecan
IV infusion
Pembrolizumab
IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated as primary therapy
* Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS) ≥50% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory
* Has a life expectancy of at least 3 months
Exclusion Criteria
* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC
* Has previously received treatment with Topoisomerase 1 inhibitors or Trop-2 targeted therapy
* Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
* Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicities requiring corticosteroids
* Has received radiation therapy to the lung that is \>30 Gray (Gy) within 6 months of the first dose of study intervention
* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
* Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration
* Has cardiac disease
* Myocardial infarction or unstable angina pectoris within 6 months of enrollment
* History of serious ventricular arrhythmia, high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications; history of QT interval prolongation
* New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of \<40%
* Has active chronic inflammatory bowel disease
* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has severe hypersensitivity (≥Grade 3) to pembrolizumab or sacituzumab govitecan and/or any of their excipients
* Has active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy
* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Has active infection requiring systemic therapy
* Has history of human immunodeficiency virus (HIV) infection
* History of hepatitis B or known active hepatitis C virus infection
* Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator
* Have not adequately recovered from major surgery or have ongoing surgical complications
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Infirmary Cancer Care ( Site 0418)
Mobile, Alabama, United States
Profound Research LLC ( Site 0444)
Oceanside, California, United States
Clermont Oncology Center ( Site 0421)
Clermont, Florida, United States
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0417)
Miami, Florida, United States
Mid Florida Hematology and Oncology Center ( Site 0416)
Orange City, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0407)
Marietta, Georgia, United States
Our Lady of the Lake RMC ( Site 0424)
Baton Rouge, Louisiana, United States
Henry Ford Hospital ( Site 0412)
Detroit, Michigan, United States
Profound Research LLC ( Site 0440)
Farmington Hills, Michigan, United States
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0425)
Minneapolis, Minnesota, United States
Basil Clinical ( Site 0441)
Inwood, New York, United States
White Plains Hospital-Center for Cancer Care ( Site 0403)
White Plains, New York, United States
Kaiser Permanente Northwest-Central Interstate--Oncology ( Site 0408)
Portland, Oregon, United States
Oregon Health & Science University ( Site 0427)
Portland, Oregon, United States
Houston Methodist Hospital ( Site 0419)
Houston, Texas, United States
Central Texas Veterans health care ( Site 0414)
Temple, Texas, United States
Orange Hospital-Clinical Trials Unit ( Site 0600)
Orange, New South Wales, Australia
Cancer Research SA-St Andrews Hospital ( Site 0603)
Adelaide, South Australia, Australia
Frankston Hospital-Oncology and Haematology ( Site 0601)
Frankston, Victoria, Australia
CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 0320)
Fortaleza, Ceará, Brazil
Hospital Tacchini ( Site 0322)
Bento Gonçalves, Rio Grande do Sul, Brazil
Hospital da Cidade de Passo Fundo ( Site 0321)
Passo Fundo, Rio Grande do Sul, Brazil
Instituto de Oncologia Saint Gallen ( Site 0317)
Santa Cruz do Sul, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0318)
Barretos, São Paulo, Brazil
A. C. Camargo Cancer Center ( Site 0324)
São Paulo, , Brazil
BC Cancer Abbotsford-Medical Oncology ( Site 0433)
Abbotsford, British Columbia, Canada
Southlake Regional Health Centre-Oncology Clinical Trials ( Site 0435)
Newmarket, Ontario, Canada
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0430)
Greenfield Park, Quebec, Canada
St. Marys Hospital Center-Oncology ( Site 0434)
Montreal, Quebec, Canada
Centre integre universitaire de sante et de services sociaux-oncology ( Site 0431)
Trois-Rivières, Quebec, Canada
Oncovida ( Site 0334)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0332)
Santiago, Region M. de Santiago, Chile
Second Affiliated hospital of Anhui Medical University ( Site 0126)
Hefei, Anhui, China
Anhui Provincial Hospital ( Site 0136)
Hefei, Anhui, China
Beijing Cancer hospital ( Site 0104)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-pneumology department ( Site 0106)
Beijing, Beijing Municipality, China
Beijing Chest Hospital,Capital Medical University ( Site 0105)
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital-Medical Oncology ( Site 0130)
Chongqing, Chongqing Municipality, China
Fujian Provincial Cancer Hospital ( Site 0131)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University ( Site 0132)
Xiamen, Fujian, China
Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 0125)
Guangzhou, Guangdong, China
Affiliated Cancer Hospital of Guangxi Medical University ( Site 0113)
Nanning, Guangxi, China
Harbin Medical University Cancer Hospital ( Site 0119)
Harbin, Heilongjiang, China
Henan Cancer Hospital ( Site 0127)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 0116)
Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 0115)
Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 0107)
Wuhan, Hubei, China
Xiangya Hospital Central South University ( Site 0124)
Changsha, Hunan, China
The Second Xiangya Hospital of Central South University ( Site 0135)
Changsha, Hunan, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0112)
Nanjing, Jiangsu, China
Nantong Tumor Hospital-Medical Oncology ( Site 0122)
Nantong, Jiangsu, China
The First Affliated Hospital of Suzhou University ( Site 0114)
Suzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University ( Site 0134)
Nanchang, Jiangxi, China
The First Hospital of Jilin University ( Site 0117)
Changchun, Jilin, China
Jilin Province Tumor Hospital-clinical research ( Site 0118)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0133)
Xi'an, Shaanxi, China
Jinan Central Hospital-oncology department ( Site 0121)
Jinan, Shandong, China
LinYi Cancer Hospital ( Site 0120)
Linyi, Shandong, China
Shanghai Chest Hospital ( Site 0101)
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center-Oncology ( Site 0102)
Shanghai, Shanghai Municipality, China
Huashan Hospital, Fudan University ( Site 0103)
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University ( Site 0129)
Chengdu, Sichuan, China
Sichuan Cancer hospital. ( Site 0128)
Chengdu, Sichuan, China
The First Affiliated Hospital, Zhejiang University ( Site 0109)
Hangzhou, Zhejiang, China
The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0110)
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital-Medical Oncology ( Site 0111)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 0108)
Hangzhou, Zhejiang, China
North Estonia Medical Centre Foundation-Chemotherapy ( Site 0621)
Tallinn, Harju, Estonia
Tartu University Hospital-Radiotherapy and oncology ( Site 0620)
Tartu, Tartu, Estonia
Universitätsmedizin Mannheim ( Site 0654)
Mannheim, Baden-Wurttemberg, Germany
Klinikum Kempten ( Site 0655)
Kempten (Allgäu), Bavaria, Germany
Klinikum Würzburg Mitte ( Site 0651)
Würzburg, Bavaria, Germany
Katholisches Klinikum Koblenz ( Site 0650)
Koblenz, Rhineland-Palatinate, Germany
Krankenhaus Martha-Maria Halle-Dölau-Klinik für Innere Medizin II ( Site 0657)
Halle, Saxony-Anhalt, Germany
Vivantes Hospital Spandau-Klinik für Innere Medizin, Hämatologie, Onkologie und Gastroenterologie- ( Site 0656)
Berlin, , Germany
Helios Klinikum Emil von Behring Berlin-Zehlendorf-Lungenklinik Heckeshorn ( Site 0653)
Berlin, , Germany
Errikos Dunant Hospital Center-Fourth Department of Oncology and Clinical Trials Unit ( Site 0141)
Athens, Attica, Greece
Sotiria Thoracic Diseases Hospital of Athens-3rd Dept of Internal Medicine, Oncology Unit ( Site 0140)
Athens, Attica, Greece
European Interbalkan Medical Center-Oncology Department ( Site 0142)
Thessaloniki, , Greece
Shaare Zedek Medical Center-Oncology ( Site 0176)
Jerusalem, , Israel
Meir Medical Center-oncology ( Site 0171)
KfarSaba, , Israel
Rabin Medical Center-Oncology ( Site 0174)
Petah Tikva, , Israel
Sourasky Medical Center-Oncology ( Site 0175)
Tel Aviv, , Israel
Yitzhak Shamir Medical Center. ( Site 0179)
Ẕerifin, , Israel
Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 0677)
Rome, Lazio, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 0674)
Bergamo, Lombardy, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0673)
Milan, Lombardy, Italy
Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 0671)
Naples, Napoli, Italy
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 0675)
Florence, Tuscany, Italy
Casa di Cura Dott. Pederzoli-LUNG-UNIT TORACIC ( Site 0670)
Peschiera del Garda, Verona, Italy
Azienda Ospedaliero Universitaria di Parma-UO Oncologia Medica ( Site 0676)
Parma, , Italy
Aichi Cancer Center ( Site 0018)
Nagoya, Aichi-ken, Japan
National Hospital Organization Shikoku Cancer Center ( Site 0008)
Matsuyama, Ehime, Japan
Kurume University Hospital ( Site 0014)
Kurume, Fukuoka, Japan
Takarazuka City Hospital ( Site 0015)
Takarazuka, Hyōgo, Japan
Kanazawa University Hospital ( Site 0019)
Kanazawa, Ishikawa-ken, Japan
Kanagawa Cancer Center ( Site 0016)
Yokohama, Kanagawa, Japan
Miyagi Cancer Center ( Site 0001)
Natori-shi, Miyagi, Japan
Sendai Kousei Hospital ( Site 0012)
Sendai, Miyagi, Japan
Niigata Cancer Center Hospital ( Site 0017)
Niigata, Niigata, Japan
Kurashiki Central Hospital ( Site 0011)
Kurashiki, Okayama-ken, Japan
Kansai Medical University Hospital ( Site 0005)
Hirakata, Osaka, Japan
Kindai University Hospital ( Site 0013)
Sayama, Osaka, Japan
Saitama Prefectural Cancer Center ( Site 0002)
Kitaadachi-gun, Saitama, Japan
Shizuoka Cancer Center ( Site 0004)
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
Tokyo Metropolitan Komagome Hospital ( Site 0020)
Bunkyo Ku, Tokyo, Japan
National Hospital Organization Kyushu Medical Center ( Site 0009)
Fukuoka, , Japan
Kyushu University Hospital ( Site 0010)
Fukuoka, , Japan
Okayama University Hospital ( Site 0007)
Okayama, , Japan
Nippon Medical School Hospital ( Site 0003)
Tokyo, , Japan
Wakayama Medical University Hospital ( Site 0006)
Wakayama, , Japan
Daugavpils Regional Hospital-Oncology Department ( Site 0194)
Daugavpils, Daugavpils Novads, Latvia
Liepjas reionl slimnca ( Site 0191)
Liepāja, , Latvia
Pauls Stradins Clinical Univeristy Hospital-Chemotherapy department ( Site 0192)
Riga, , Latvia
RIGA EAST UNIVERSITY HOSPITAL ,Oncology Centre of Latvia-Out-patient and Day patient facility of Ch ( Site 0193)
Riga, , Latvia
Hospital of Lithuanian University of Health Sciences Kauno klinikos-Pulmonology ( Site 0692)
Kaunas, Kaunas County, Lithuania
Vilnius University Hospital Santaros Clinics Affiliate - National Cancer Center ( Site 0691)
Vilnius, , Lithuania
Hospital Raja Perempuan Zainab II-Medical Department ( Site 0035)
Kota Bharu, Kelantan, Malaysia
Hospital Pulau Pinang-Oncology, radiotherapy and palliat ( Site 0034)
George Town, Pulau Pinang, Malaysia
Beacon Hospital Sdn Bhd ( Site 0033)
Petaling Jaya, Selangor, Malaysia
COI Tijuana - Centro Oncológico Internacional ( Site 0350)
Tijuana, Estado de Baja California, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología ( Site 0352)
Monterrey, Nuevo León, Mexico
Medical Care and Research SA de CV ( Site 0353)
Mérida, Yucatán, Mexico
Centro de Investigacion Medica Aguascalientes ( Site 0340)
Aguascalientes, , Mexico
Oaxaca Site Management Organization ( Site 0346)
Oaxaca City, , Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 0351)
Oaxaca City, , Mexico
Clinica Vallesur - AUNA ( Site 0360)
Arequipa, Ariqipa, Peru
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 0362)
Concepción, Departamento de Junín, Peru
Centro de investigacion Clínica Trujillo ( Site 0358)
Trujillo, La Libertad, Peru
Detecta Clínica ( Site 0364)
Surquillo, Lima region, Peru
Clínica Internacional - Sede San Borja ( Site 0356)
Lima, , Peru
Instituto Neuro Cardiovascular de las Americas ( Site 0365)
Lima, , Peru
Hospital Cayetano Heredia ( Site 0361)
Lima, , Peru
Metro Davao Medical and Research Center ( Site 0047)
Davao City, Davao Del Sur, Philippines
ST. LUKE'S MEDICAL CENTER ( Site 0046)
Quezon City, National Capital Region, Philippines
Cebu Doctors University Hospital ( Site 0045)
Cebu, , Philippines
Med-Polonia Sp. z o. o. ( Site 0204)
Poznan, Greater Poland Voivodeship, Poland
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0208)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 0201)
Siedlce, Masovian Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0200)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 0203)
Przemyśl, Podkarpackie Voivodeship, Poland
Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 0202)
Prabuty, Pomeranian Voivodeship, Poland
Szpital Rejonowy im. dr. J. Rostka w Raciborzu ( Site 0207)
Racibórz, Silesian Voivodeship, Poland
Gral Medical SRL-Medical Oncology ( Site 0220)
Bucharest, București, Romania
Cardiomed SRL Cluj-Napoca ( Site 0217)
Cluj-Napoca, Cluj, Romania
Amethyst Radiotherapy Center-Oncologie Medicala ( Site 0216)
Florești, Cluj, Romania
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 0215)
Craiova, Dolj, Romania
Cabinet Medical Oncomed ( Site 0219)
Timișoara, Timiș County, Romania
Institutul Oncologic-Oncologie Medicala ( Site 0218)
Cluj-Napoca, , Romania
Chonnam National University Hwasun Hospital-Pulmonology ( Site 0061)
Hwasun, Jeonranamdo, South Korea
Pusan National University Yangsan Hospital ( Site 0060)
Pusan, Kyongsangnam-do, South Korea
Chungnam national university hospital-Department of Internal Medicine ( Site 0063)
Daejeon, Taejon-Kwangyokshi, South Korea
Asan Medical Center ( Site 0064)
Seoul, , South Korea
Korea University Guro Hospital-Internal Medicine ( Site 0062)
Seoul, , South Korea
Chung Shan Medical University Hospital ( Site 0078)
Taichung, Taichung, Taiwan
National Taiwan University Cancer Center (NTUCC) ( Site 0079)
Taipei City, Taipei, Taiwan
E-Da hospital ( Site 0075)
Kaohsiung City, , Taiwan
China Medical University Hospital-Internal Medicine ( Site 0083)
Taichung, , Taiwan
National Cheng Kung University Hospital-Clinical Trial Center ( Site 0076)
Tainan, , Taiwan
National Taiwan University Hospital-Internal Medicine ( Site 0080)
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 0082)
Taoyuan District, , Taiwan
Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0097)
Bangkok, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital ( Site 0090)
Bangkok, Bangkok, Thailand
Lampang Cancer Hospital ( Site 0098)
Lampang, Changwat Lampang, Thailand
Songklanagarind hospital ( Site 0091)
Hat Yai, Changwat Songkhla, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 0092)
Muang, Chiang Mai, Thailand
Sunpasitthiprasong Hospital ( Site 0093)
Ubon Ratchathani, , Thailand
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0265)
Ankara, , Turkey (Türkiye)
Liv Hospital Ankara-Oncology ( Site 0274)
Ankara, , Turkey (Türkiye)
Ankara City Hospital-Medical Oncology ( Site 0268)
Ankara, , Turkey (Türkiye)
Trakya University-Medical Oncology ( Site 0270)
Edirne, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 0267)
Istanbul, , Turkey (Türkiye)
VM Medical Park Pendik Hospital ( Site 0271)
Istanbul, , Turkey (Türkiye)
I.E.U. Medical Point Hastanesi-Oncology ( Site 0266)
Izmir, , Turkey (Türkiye)
Mersin Sehir Eğitim ve Araştırma Hastanesi ( Site 0275)
Mersin, , Turkey (Türkiye)
Leicester Royal Infirmary-HOPE Clinical Trials Unit ( Site 0300)
Leicester, Leicestershire, United Kingdom
St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 0302)
London, London, City of, United Kingdom
University College London Hospital ( Site 0305)
London, London, City of, United Kingdom
The Clatterbridge Cancer Centre ( Site 0303)
Metropolitan Borough of Wirral, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-3475-D46
Identifier Type: OTHER
Identifier Source: secondary_id
PHRR230203-005387
Identifier Type: REGISTRY
Identifier Source: secondary_id
jRCT2031230031
Identifier Type: REGISTRY
Identifier Source: secondary_id
2023-503501-11-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1287-4239
Identifier Type: REGISTRY
Identifier Source: secondary_id
2022-000836-49
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3475-D46
Identifier Type: -
Identifier Source: org_study_id